WallStreetZenWallStreetZen

NASDAQ: PCSA
Processa Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for PCSA

Based on 1 analyst offering 12 month price targets for Processa Pharmaceuticals Inc

Min Forecast
$1.00+170.27%
Avg Forecast
$1.00+170.27%
Max Forecast
$1.00+170.27%

Should I buy or sell PCSA stock?

Based on 1 analyst offering ratings for Processa Pharmaceuticals Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their PCSA stock forecasts and price targets.

PCSA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-09-02

1 of 1

Forecast return on equity

Is PCSA forecast to generate an efficient return?

Company
N/A
Industry
246.43%
Market
143.41%

Forecast return on assets

Is PCSA forecast to generate an efficient return on assets?

Company
N/A
Industry
107.61%

PCSA earnings per share forecast

What is PCSA's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.46
Avg 2 year Forecast
-$0.23
Avg 3 year Forecast
-$0.27

PCSA revenue forecast

What is PCSA's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$54.1M

PCSA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PCSA$0.37$1.00+170.27%Buy
CURX$0.67N/AN/A
HOTH$1.40$5.00+257.14%Strong Buy
CRIS$1.48$17.00+1,048.65%Buy
BCTX$10.00$40.00+300.00%Buy
View Top Biotech Stocks

Processa Pharmaceuticals Stock Forecast FAQ

Is Processa Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: PCSA) stock is to Buy PCSA stock.

Out of 1 analyst, 0 (0%) are recommending PCSA as a Strong Buy, 1 (100%) are recommending PCSA as a Buy, 0 (0%) are recommending PCSA as a Hold, 0 (0%) are recommending PCSA as a Sell, and 0 (0%) are recommending PCSA as a Strong Sell.

If you're new to stock investing, here's how to buy Processa Pharmaceuticals stock.

What is PCSA's earnings growth forecast for 2025-2027?

(NASDAQ: PCSA) Processa Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 36.79%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41.55%.

Processa Pharmaceuticals's earnings in 2025 is -$12,881,734.On average, 4 Wall Street analysts forecast PCSA's earnings for 2025 to be -$23,110,259, with the lowest PCSA earnings forecast at -$23,190,818, and the highest PCSA earnings forecast at -$22,732,641. On average, 4 Wall Street analysts forecast PCSA's earnings for 2026 to be -$11,811,910, with the lowest PCSA earnings forecast at -$15,296,071, and the highest PCSA earnings forecast at -$7,929,991.

In 2027, PCSA is forecast to generate -$13,352,594 in earnings, with the lowest earnings forecast at -$12,828,963 and the highest earnings forecast at -$13,745,318.

What is PCSA's revenue growth forecast for 2025-2028?

(NASDAQ: PCSA) Processa Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 107.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 26.22%.

Processa Pharmaceuticals's revenue in 2025 is $0.On average, 3 Wall Street analysts forecast PCSA's revenue for 2025 to be $0, with the lowest PCSA revenue forecast at $0, and the highest PCSA revenue forecast at $0. On average, 3 Wall Street analysts forecast PCSA's revenue for 2026 to be $0, with the lowest PCSA revenue forecast at $0, and the highest PCSA revenue forecast at $0.

In 2028, PCSA is forecast to generate $2,725,751,879 in revenue, with the lowest revenue forecast at $2,618,860,636 and the highest revenue forecast at $2,805,907,725.

What is PCSA's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: PCSA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 107.61%.

What is PCSA's Price Target?

According to 1 Wall Street analyst that have issued a 1 year PCSA price target, the average PCSA price target is $1.00, with the highest PCSA stock price forecast at $1.00 and the lowest PCSA stock price forecast at $1.00.

The Wall Street analyst predicted that Processa Pharmaceuticals's share price could reach $1.00 by Sep 2, 2026. The average Processa Pharmaceuticals stock price prediction forecasts a potential upside of 170.27% from the current PCSA share price of $0.37.

What is PCSA's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: PCSA) Processa Pharmaceuticals's current Earnings Per Share (EPS) is -$2.32. On average, analysts forecast that PCSA's EPS will be -$0.46 for 2025, with the lowest EPS forecast at -$0.46, and the highest EPS forecast at -$0.45. On average, analysts forecast that PCSA's EPS will be -$0.23 for 2026, with the lowest EPS forecast at -$0.30, and the highest EPS forecast at -$0.16. In 2027, PCSA's EPS is forecast to hit -$0.27 (min: -$0.25, max: -$0.27).

What is PCSA's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: PCSA) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.